353 related articles for article (PubMed ID: 30987401)
1. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules.
Nebbioso M; Lambiase A; Cerini A; Limoli PG; La Cava M; Greco A
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987401
[TBL] [Abstract][Full Text] [Related]
2. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Yaspan BL; Williams DF; Holz FG; Regillo CD; Li Z; Dressen A; van Lookeren Campagne M; Le KN; Graham RR; Beres T; Bhangale TR; Honigberg LA; Smith A; Henry EC; Ho C; Strauss EC;
Sci Transl Med; 2017 Jun; 9(395):. PubMed ID: 28637922
[TBL] [Abstract][Full Text] [Related]
3. Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options.
Fernandes AR; Zielińska A; Sanchez-Lopez E; Dos Santos T; Garcia ML; Silva AM; Karczewski J; Souto EB
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269743
[TBL] [Abstract][Full Text] [Related]
4. Treatment of dry age-related macular degeneration: A review.
Girgis S; Lee LR
Clin Exp Ophthalmol; 2023 Nov; 51(8):835-852. PubMed ID: 37737509
[TBL] [Abstract][Full Text] [Related]
5. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.
Gemenetzi M; Lotery AJ; Patel PJ
Eye (Lond); 2017 Jan; 31(1):1-9. PubMed ID: 27716750
[TBL] [Abstract][Full Text] [Related]
6. Investigational drugs in clinical trials for macular degeneration.
Tolentino MJ; Tolentino AJ
Expert Opin Investig Drugs; 2022 Oct; 31(10):1067-1085. PubMed ID: 35962560
[TBL] [Abstract][Full Text] [Related]
7. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
8. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
9. Dry age-related macular degeneration: recent progress of therapeutic approaches.
Kuno N; Fujii S
Curr Mol Pharmacol; 2011 Nov; 4(3):196-232. PubMed ID: 21545354
[TBL] [Abstract][Full Text] [Related]
10. The complement system: a novel therapeutic target for age-related macular degeneration.
Shughoury A; Sevgi DD; Ciulla TA
Expert Opin Pharmacother; 2023; 24(17):1887-1899. PubMed ID: 37691588
[TBL] [Abstract][Full Text] [Related]
11. Update on geographic atrophy in age-related macular degeneration.
Biarnés M; Monés J; Alonso J; Arias L
Optom Vis Sci; 2011 Jul; 88(7):881-9. PubMed ID: 21532519
[TBL] [Abstract][Full Text] [Related]
12. Age-related macular degeneration therapy: a review.
Ammar MJ; Hsu J; Chiang A; Ho AC; Regillo CD
Curr Opin Ophthalmol; 2020 May; 31(3):215-221. PubMed ID: 32205470
[TBL] [Abstract][Full Text] [Related]
13. New Treatment Modalities for Geographic Atrophy.
Kandasamy R; Wickremasinghe S; Guymer R
Asia Pac J Ophthalmol (Phila); 2017; 6(6):508-513. PubMed ID: 28905539
[TBL] [Abstract][Full Text] [Related]
14. Complement cascade inhibition in geographic atrophy: a review.
Desai D; Dugel PU
Eye (Lond); 2022 Feb; 36(2):294-302. PubMed ID: 34999723
[TBL] [Abstract][Full Text] [Related]
15. Patient acceptability of intravitreal complement inhibitors in geographic atrophy (GA): protocol for a UK-based cross-sectional study.
Dinah C; Enoch J; Ghulakhszian A; Sekhon M; Crabb DP; Taylor DJ
BMJ Open; 2024 Jan; 14(1):e075713. PubMed ID: 38238063
[TBL] [Abstract][Full Text] [Related]
16. Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy.
Jack LS; Sadiq MA; Do DV; Nguyen QD
Dev Ophthalmol; 2016; 55():302-9. PubMed ID: 26501510
[TBL] [Abstract][Full Text] [Related]
17. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.
Boyer DS; Schmidt-Erfurth U; van Lookeren Campagne M; Henry EC; Brittain C
Retina; 2017 May; 37(5):819-835. PubMed ID: 27902638
[TBL] [Abstract][Full Text] [Related]
18. The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.
Borchert GA; Shamsnajafabadi H; Hu ML; De Silva SR; Downes SM; MacLaren RE; Xue K; Cehajic-Kapetanovic J
Cells; 2023 Aug; 12(16):. PubMed ID: 37626902
[TBL] [Abstract][Full Text] [Related]
19. Drugs in Phase II clinical trials for the treatment of age-related macular degeneration.
Tolentino MJ; Dennrick A; John E; Tolentino MS
Expert Opin Investig Drugs; 2015 Feb; 24(2):183-99. PubMed ID: 25243494
[TBL] [Abstract][Full Text] [Related]
20. New approaches and potential treatments for dry age-related macular degeneration.
Damico FM; Gasparin F; Scolari MR; Pedral LS; Takahashi BS
Arq Bras Oftalmol; 2012; 75(1):71-6. PubMed ID: 22552424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
